会计年度:2021-12-31收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 测试业务(WuXiTesting) | 4,525,111,300.00 | 3,090,597,000.00 | 1,434,514,300.00 | 31.70 |
| 国内新药研发服务部(WuXiDDSU) | 1,251,039,900.00 | 701,815,100.00 | 549,224,800.00 | 43.90 |
| 合计 | 22,902,385,129.11 | 14,592,255,587.53 | 8,310,129,541.58 | 36.28 |
| 化学业务(WuXiChemistry) | 14,087,220,200.00 | 8,521,976,100.00 | 5,565,244,100.00 | 39.51 |
| 其他(补充) | 27,520,041.18 | 14,424,442.23 | 13,095,598.95 | 47.59 |
| 生物学业务(WuXiBiology) | 1,985,092,500.00 | 1,216,249,800.00 | 768,842,700.00 | 38.73 |
| 细胞及基因疗法CTDMO业务(WuXiATU) | 1,026,401,200.00 | 1,047,193,200.00 | -20,792,000.00 | -2.03 |
|
会计年度:2020-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| CDMO业务 | 5,282,053,600.00 | 3,105,030,300.00 | 2,177,023,300.00 | 41.22 |
| CRO业务 | 11,231,273,000.00 | 7,137,657,200.00 | 4,093,615,800.00 | 36.45 |
| 合计 | 16,535,431,465.41 | 10,253,275,738.89 | 6,282,155,726.52 | 37.99 |
| 其他(补充) | 22,104,822.98 | 10,588,276.37 | 11,516,546.61 | 52.10 |
|
会计年度:2019-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| CDMO/CMO业务 | 3,752,054,500.00 | 2,253,475,600.00 | 1,498,578,900.00 | 39.94 |
| CRO业务 | 9,098,933,000.00 | 5,586,651,200.00 | 3,512,281,800.00 | 38.60 |
| 合计 | 12,872,206,437.16 | 7,858,299,235.34 | 5,013,907,201.82 | 38.95 |
| 其他(补充) | 21,218,924.21 | 18,172,398.56 | 3,046,525.65 | 14.36 |
|
会计年度:2018-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| CDMO/CMO业务 | 2,698,885,500.00 | 1,577,430,000.00 | 1,121,455,500.00 | 41.55 |
| CRO业务 | 6,902,187,000.00 | 4,234,404,400.00 | 2,667,782,600.00 | 38.65 |
| 合计 | 9,613,683,593.04 | 5,820,982,800.87 | 3,792,700,792.17 | 39.45 |
| 平衡项目 | -34.38 | 38.50 | -72.88 | 211.98 |
| 其他(补充) | 12,611,127.42 | 9,148,362.37 | 3,462,765.05 | 27.46 |
|
